Eli Lilly reported $19.3 billion in revenue for Q4 and is expanding its GLP-1 franchise into immunology and inflammation. Ongoing trials target asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Generate Biomedicines has filed for a $100 million IPO to advance its AI-driven drug discovery platform focused on severe asthma therapies. This Phase 3 biotech aims to leverage its technology to enhance treatment options in this area.

A new CDC report reveals that asthma diagnoses in the U.S. increased by 4.3 million from 2001 to 2009, highlighting a growing public health concern. This trend underscores the need for enhanced awareness and advocacy efforts in managing asthma.

The CDC reports a decline in asthma death rates among children under 18 since 1999, highlighting progress in managing childhood asthma. This report underscores the importance of continued advocacy and awareness efforts in addressing this public health issue.

CDC reports indicate improvements in health insurance coverage for children since 2005, though overall coverage varies significantly by state. The reports also highlight trends in health habits and the prevalence of conditions like diabetes and asthma.